SynthesisBreast cancer research and treatment2016
Progestin and breast cancer risk: a systematic review.
Synthesis in Breast cancer research and treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Depot medroxyprogesterone acetate and breast cancer: a systematic review.Archives of gynecology and obstetrics · 2024Pooled it
- Contraceptive use with breast cancer incidence in Indonesia.Breast disease · 2024Pooled it
- Expression and potential molecular mechanisms of miR‑204‑5p in breast cancer, based on bioinformatics and a meta‑analysis of 2,306 cases.Molecular medicine reports · 2019Pooled it
- Association of lifestyle factors with breast cancer incidence: An overview of systematic reviews.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Recent strategies in diagnosis, screening, prevention, and treatment of breast cancer in young women.Discover oncology · 2025Review
- Comparative reproductive pathology, a walk on the wild side.F&S reports · 2025Article
- Conception and Concern: A Review of Breast Cancer Risk in Assisted Reproductive Technology.International journal of biological sciences · 2025Review
- Review
- Re-Evaluating the Association Between Hormonal Contraception and Breast Cancer Risk.Breast cancer (Dove Medical Press) · 2023Review
- Hormonal contraception and risk of breast cancer and breast cancer in situ among Swedish women 15-34 years of age: A nationwide register-based study.The Lancet regional health. Europe · 2022Article
- Contraception During Perimenopause: Practical Guidance.International journal of women's health · 2022Review
- Article
- After the Affordable Care Act: the Effects of the Health Safety Net and the Medicaid Expansion on Latinxs' Use of Behavioral Healthcare in the US.The journal of behavioral health services & research · 2021Article
- The Association Between Triglyceride-Glucose Index as a Marker of Insulin Resistance and the Risk of Breast Cancer.Frontiers in endocrinology · 2021Article
- LncRNA SNHG8 Serves as an Oncogene in Breast Cancer Through miR-634/ZBTB20 Axis.Cancer management and research · 2021Article
- Breast Cancer Risk with Progestin Subdermal Implants: A Challenge in Patients Counseling.Frontiers in endocrinology · 2021Review
- GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf.ACS central science · 2020Article
- Executive Summary of the Early-Onset Breast Cancer Evidence Review Conference.Obstetrics and gynecology · 2020Review
- Progesterone and Breast Cancer.Endocrine reviews · 2020Review
- Identification of Potential Prognostic Biomarkers for Breast Cancer Based on lncRNA-TF-Associated ceRNA Network and Functional Module.BioMed research international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
This systematic review summarizes research on the use of progestin and breast cancer risk. Although mainly used for contraception, progestin can help treat menstrual disorders, and benign breast, uterine, and ovarian diseases. Breast cancer is the leading site of new, non-skin, cancers in females in the United States, and possible factors that may modulate breast cancer risk need to be identified. ProQuest (Ann Arbor, MI) and PubMed-Medline (US National Library of Medicine, Bethesda MD, USA) databases were used to search for epidemiologic studies from 2000 to 2015 that examined the association between progestin and breast cancer. Search terms included epidemiologic studies + progesterone or progestin or progestogen or contraceptive or contraceptive agents + breast cancer or breast neoplasms. A total of six studies were included in the review. Five of the six studies reported no association between progestin-only formulations (including norethindrone oral contraceptives, depot medroxyprogesterone acetate, injectable, levonorgestrel system users, implantable and intrauterine devices) and breast cancer risk. Duration of use was examined in a few studies with heterogeneous results. Unlike studies of other oral contraceptives, studies indicate that progestin-only formulations do not increase the risk of breast cancer, although the literature is hampered by small sample sizes. Future research is needed to corroborate these findings, as further understanding of synthetic progesterone may initiate new prescription practices or guidelines for women's health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.